CYP19A1 and breast carcinoma: In particular, aromatase inhibitors (AIs), which are linked to joint and muscular symptoms and are referred to as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) (60), are frequently used to treat hormone-positive (HR+) breast cancer in women.